Form 4: CEO Bendheim Sells PAHC Stock via 10b5-1 Plan

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold 72,198 shares of Class A Common Stock in early February 2026 through a pre-arranged 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO, and a 10% owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, reported sales of Class A Common Stock.
• A total of 72,198 shares were sold across four transactions on February 10 and 11, 2026.
• The sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Weighted average sale prices ranged from $51.6107 to $52.173 per share.
• Following these transactions, BFI Co., LLC beneficially owns 50,760 shares, and Jack Bendheim directly holds 16,840 shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the 10b5-1 plan indicates pre-planning, significant insider selling by the CEO and a major shareholder can still raise questions about future growth prospects or valuation.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new information.

Negatives

• Significant insider selling by the CEO and a 10% owner could be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock is fully valued.
• The total value of shares sold exceeds $3.7 million based on the weighted average prices.

Risks

• Potential negative market perception due to significant insider selling by key management and a major shareholder.

Future Outlook

NA

Management Comments

• Jack Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider selling, even when pre-arranged via a 10b5-1 plan, can sometimes be interpreted by the market as a signal of management's view on the company's valuation or future prospects. In the animal health sector, where long-term growth and innovation are key, such sales by a CEO and significant owner warrant attention, though the pre-planned nature mitigates immediate concerns of opportunistic selling.

Comparison to Industry Standards

• StockSavvy.ai observes that 10b5-1 plans are a common mechanism for insiders to sell shares systematically and avoid accusations of trading on material non-public information. Companies like Zoetis Inc. (ZTS) and Elanco Animal Health Incorporated (ELAN) also see their executives utilize such plans for personal financial planning. The volume of shares sold by Mr. Bendheim and BFI Co., LLC, representing a notable portion of their indirect holdings, is significant but not unprecedented for long-serving executives managing their personal portfolios.

Related Party Transactions

• Sales of Class A Common Stock by BFI Co., LLC, an entity over which Jack Bendheim (CEO, Director, 10% Owner) exercises voting and dispositive power, are considered related party transactions.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially impacting investor confidence and stock price.
• Management/Employees: No direct impact mentioned, but general market sentiment could indirectly affect morale.

Key Dates

Recommendation

The significant insider selling by the CEO and a major shareholder, even under a 10b5-1 plan, suggests that these key insiders may view the stock as fully valued or anticipate limited upside in the near term. While not an immediate 'sell' signal due to the pre-planned nature, it warrants caution. Investors should 'hold' and monitor future company performance and additional insider activity before making further investment decisions, as this action could indicate a lack of strong conviction from leadership.

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, Insider Selling, Form 4, 10b5-1 Plan, CEO Stock Sale, Animal Health, Equity Sales